Bis(bipyridine)ruthenium(II) Ferrocenyl β‐Diketonate Complexes: Exhibiting Nanomolar Potency against Human Cancer Cell Lines

The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl β‐diketonate complexes, [(bpy)2Ru(Fc‐acac)][PF6] (bpy=2,2′‐bipyridine; Fc‐acac=functionalized ferrocenyl β‐diketonate ligand) are reported. Alongside clinical platinum drugs, these bimetallic ruthenium‐iron complexes h...

Full description

Saved in:
Bibliographic Details
Published inChemistry : a European journal Vol. 27; no. 11; pp. 3737 - 3744
Main Authors Allison, Matthew, Caramés‐Méndez, Pablo, Pask, Christopher M., Phillips, Roger M., Lord, Rianne M., McGowan, Patrick C.
Format Journal Article
LanguageEnglish
Published WEINHEIM Wiley 19.02.2021
Wiley Subscription Services, Inc
Subjects
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Bimetals
Bioassays
bioinorganic
Biotechnology
Cancer
Carboplatin
Cell Line, Tumor
Chemistry
Chemistry, Multidisciplinary
Cisplatin
Colon
Colorectal cancer
Comet Assay
Coordination Complexes - chemistry
Coordination Complexes - pharmacology
Coordination compounds
Cytotoxicity
Damage detection
DNA damage
hetero-bimetallic
Humans
Hypoxia
iron
Microbial Sensitivity Tests
Neoplasms - drug therapy
Neoplasms - pathology
Oxaliplatin
Pancreatic cancer
Pancreatic carcinoma
Physical Sciences
Platinum
Ruthenium
Ruthenium - chemistry
Ruthenium - pharmacology
Ruthenium compounds
Science & Technology
Toxicity
Tumor cell lines
bioinorganic
ruthenium
iron
cancer
hetero-bimetallic
Online AccessGet full text
ISSN0947-6539
1521-3765
1521-3765
DOI10.1002/chem.202004024

Cover

Abstract The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl β‐diketonate complexes, [(bpy)2Ru(Fc‐acac)][PF6] (bpy=2,2′‐bipyridine; Fc‐acac=functionalized ferrocenyl β‐diketonate ligand) are reported. Alongside clinical platinum drugs, these bimetallic ruthenium‐iron complexes have been screened for their cytotoxicity against MIA PaCa‐2 (human pancreatic carcinoma), HCT116 p53+/+ (human colon carcinoma, p53‐wild type) and ARPE‐19 (human retinal pigment epithelial) cell lines. With the exception of one complex, the library exhibit nanomolar potency against cancerous cell lines, and their relative potencies are up to 40x, 400x and 72x more cytotoxic than cisplatin, carboplatin and oxaliplatin, respectively. Under hypoxic conditions, the complexes remain cytotoxic (sub‐micromolar range), highlighting their potential in targeting hypoxic tumor regions. The Comet assay was used to determine their ability to damage DNA, and results show dose dependent damage which correlates well with the cytotoxicity results. Their potential to treat bacterial and fungal strains has been determined, and highlight complexes have selective growth inhibition of up to 87–100 % against Staphylococcus aureus and Candida albicans. Hetero‐bimetallic ruthenium(II)‐ferrocenyl complexes with nanomolar potency towards cancer cell lines, which retain their activity in hypoxic conditions, show dose‐dependent DNA damage and are active inhibitors of bacterial and fungal strains.
AbstractList The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl β‐diketonate complexes, [(bpy) 2 Ru(Fc‐acac)][PF 6 ] (bpy=2,2′‐bipyridine; Fc‐acac=functionalized ferrocenyl β‐diketonate ligand) are reported. Alongside clinical platinum drugs, these bimetallic ruthenium‐iron complexes have been screened for their cytotoxicity against MIA PaCa‐2 (human pancreatic carcinoma), HCT116 p53 +/+ (human colon carcinoma, p53 ‐wild type) and ARPE‐19 (human retinal pigment epithelial) cell lines. With the exception of one complex, the library exhibit nanomolar potency against cancerous cell lines, and their relative potencies are up to 40x, 400x and 72x more cytotoxic than cisplatin, carboplatin and oxaliplatin, respectively. Under hypoxic conditions, the complexes remain cytotoxic (sub‐micromolar range), highlighting their potential in targeting hypoxic tumor regions. The Comet assay was used to determine their ability to damage DNA, and results show dose dependent damage which correlates well with the cytotoxicity results. Their potential to treat bacterial and fungal strains has been determined, and highlight complexes have selective growth inhibition of up to 87–100 % against Staphylococcus aureus and Candida albicans .
The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl beta-diketonate complexes, [(bpy)(2)Ru(Fc-acac)][PF6] (bpy=2,2 '-bipyridine; Fc-acac=functionalized ferrocenyl beta-diketonate ligand) are reported. Alongside clinical platinum drugs, these bimetallic ruthenium-iron complexes have been screened for their cytotoxicity against MIA PaCa-2 (human pancreatic carcinoma), HCT116 p53(+/+) (human colon carcinoma, p53-wild type) and ARPE-19 (human retinal pigment epithelial) cell lines. With the exception of one complex, the library exhibit nanomolar potency against cancerous cell lines, and their relative potencies are up to 40x, 400x and 72x more cytotoxic than cisplatin, carboplatin and oxaliplatin, respectively. Under hypoxic conditions, the complexes remain cytotoxic (sub-micromolar range), highlighting their potential in targeting hypoxic tumor regions. The Comet assay was used to determine their ability to damage DNA, and results show dose dependent damage which correlates well with the cytotoxicity results. Their potential to treat bacterial and fungal strains has been determined, and highlight complexes have selective growth inhibition of up to 87-100 % against Staphylococcus aureus and Candida albicans.
The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl β‐diketonate complexes, [(bpy)2Ru(Fc‐acac)][PF6] (bpy=2,2′‐bipyridine; Fc‐acac=functionalized ferrocenyl β‐diketonate ligand) are reported. Alongside clinical platinum drugs, these bimetallic ruthenium‐iron complexes have been screened for their cytotoxicity against MIA PaCa‐2 (human pancreatic carcinoma), HCT116 p53+/+ (human colon carcinoma, p53‐wild type) and ARPE‐19 (human retinal pigment epithelial) cell lines. With the exception of one complex, the library exhibit nanomolar potency against cancerous cell lines, and their relative potencies are up to 40x, 400x and 72x more cytotoxic than cisplatin, carboplatin and oxaliplatin, respectively. Under hypoxic conditions, the complexes remain cytotoxic (sub‐micromolar range), highlighting their potential in targeting hypoxic tumor regions. The Comet assay was used to determine their ability to damage DNA, and results show dose dependent damage which correlates well with the cytotoxicity results. Their potential to treat bacterial and fungal strains has been determined, and highlight complexes have selective growth inhibition of up to 87–100 % against Staphylococcus aureus and Candida albicans. Hetero‐bimetallic ruthenium(II)‐ferrocenyl complexes with nanomolar potency towards cancer cell lines, which retain their activity in hypoxic conditions, show dose‐dependent DNA damage and are active inhibitors of bacterial and fungal strains.
The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl β‐diketonate complexes, [(bpy)2Ru(Fc‐acac)][PF6] (bpy=2,2′‐bipyridine; Fc‐acac=functionalized ferrocenyl β‐diketonate ligand) are reported. Alongside clinical platinum drugs, these bimetallic ruthenium‐iron complexes have been screened for their cytotoxicity against MIA PaCa‐2 (human pancreatic carcinoma), HCT116 p53+/+ (human colon carcinoma, p53‐wild type) and ARPE‐19 (human retinal pigment epithelial) cell lines. With the exception of one complex, the library exhibit nanomolar potency against cancerous cell lines, and their relative potencies are up to 40x, 400x and 72x more cytotoxic than cisplatin, carboplatin and oxaliplatin, respectively. Under hypoxic conditions, the complexes remain cytotoxic (sub‐micromolar range), highlighting their potential in targeting hypoxic tumor regions. The Comet assay was used to determine their ability to damage DNA, and results show dose dependent damage which correlates well with the cytotoxicity results. Their potential to treat bacterial and fungal strains has been determined, and highlight complexes have selective growth inhibition of up to 87–100 % against Staphylococcus aureus and Candida albicans.
The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl β-diketonate complexes, [(bpy)2 Ru(Fc-acac)][PF6 ] (bpy=2,2'-bipyridine; Fc-acac=functionalized ferrocenyl β-diketonate ligand) are reported. Alongside clinical platinum drugs, these bimetallic ruthenium-iron complexes have been screened for their cytotoxicity against MIA PaCa-2 (human pancreatic carcinoma), HCT116 p53+/+ (human colon carcinoma, p53-wild type) and ARPE-19 (human retinal pigment epithelial) cell lines. With the exception of one complex, the library exhibit nanomolar potency against cancerous cell lines, and their relative potencies are up to 40x, 400x and 72x more cytotoxic than cisplatin, carboplatin and oxaliplatin, respectively. Under hypoxic conditions, the complexes remain cytotoxic (sub-micromolar range), highlighting their potential in targeting hypoxic tumor regions. The Comet assay was used to determine their ability to damage DNA, and results show dose dependent damage which correlates well with the cytotoxicity results. Their potential to treat bacterial and fungal strains has been determined, and highlight complexes have selective growth inhibition of up to 87-100 % against Staphylococcus aureus and Candida albicans.The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl β-diketonate complexes, [(bpy)2 Ru(Fc-acac)][PF6 ] (bpy=2,2'-bipyridine; Fc-acac=functionalized ferrocenyl β-diketonate ligand) are reported. Alongside clinical platinum drugs, these bimetallic ruthenium-iron complexes have been screened for their cytotoxicity against MIA PaCa-2 (human pancreatic carcinoma), HCT116 p53+/+ (human colon carcinoma, p53-wild type) and ARPE-19 (human retinal pigment epithelial) cell lines. With the exception of one complex, the library exhibit nanomolar potency against cancerous cell lines, and their relative potencies are up to 40x, 400x and 72x more cytotoxic than cisplatin, carboplatin and oxaliplatin, respectively. Under hypoxic conditions, the complexes remain cytotoxic (sub-micromolar range), highlighting their potential in targeting hypoxic tumor regions. The Comet assay was used to determine their ability to damage DNA, and results show dose dependent damage which correlates well with the cytotoxicity results. Their potential to treat bacterial and fungal strains has been determined, and highlight complexes have selective growth inhibition of up to 87-100 % against Staphylococcus aureus and Candida albicans.
The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl β-diketonate complexes, [(bpy) Ru(Fc-acac)][PF ] (bpy=2,2'-bipyridine; Fc-acac=functionalized ferrocenyl β-diketonate ligand) are reported. Alongside clinical platinum drugs, these bimetallic ruthenium-iron complexes have been screened for their cytotoxicity against MIA PaCa-2 (human pancreatic carcinoma), HCT116 p53 (human colon carcinoma, p53-wild type) and ARPE-19 (human retinal pigment epithelial) cell lines. With the exception of one complex, the library exhibit nanomolar potency against cancerous cell lines, and their relative potencies are up to 40x, 400x and 72x more cytotoxic than cisplatin, carboplatin and oxaliplatin, respectively. Under hypoxic conditions, the complexes remain cytotoxic (sub-micromolar range), highlighting their potential in targeting hypoxic tumor regions. The Comet assay was used to determine their ability to damage DNA, and results show dose dependent damage which correlates well with the cytotoxicity results. Their potential to treat bacterial and fungal strains has been determined, and highlight complexes have selective growth inhibition of up to 87-100 % against Staphylococcus aureus and Candida albicans.
Author Phillips, Roger M.
Lord, Rianne M.
McGowan, Patrick C.
Caramés‐Méndez, Pablo
Allison, Matthew
Pask, Christopher M.
Author_xml – sequence: 1
  givenname: Matthew
  surname: Allison
  fullname: Allison, Matthew
  organization: University of Leeds
– sequence: 2
  givenname: Pablo
  surname: Caramés‐Méndez
  fullname: Caramés‐Méndez, Pablo
  organization: University of Huddersfield
– sequence: 3
  givenname: Christopher M.
  surname: Pask
  fullname: Pask, Christopher M.
  organization: University of Leeds
– sequence: 4
  givenname: Roger M.
  surname: Phillips
  fullname: Phillips, Roger M.
  organization: University of Huddersfield
– sequence: 5
  givenname: Rianne M.
  orcidid: 0000-0001-9981-129X
  surname: Lord
  fullname: Lord, Rianne M.
  email: r.lord@uea.ac.uk
  organization: University of Bradford
– sequence: 6
  givenname: Patrick C.
  surname: McGowan
  fullname: McGowan, Patrick C.
  email: p.c.mcgowan@leeds.ac.uk
  organization: University of Leeds
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33073884$$D View this record in MEDLINE/PubMed
BookMark eNqNks1uEzEUhS1URNPCliWyxCYVmuCf-XN3ME1JpPCzgPXI47lpXGbsYHtEZ1UegWfhQXgIngRXSYtUCcHKXnzn3qNzzxE6MNYAQk8pmVFC2Eu1gX7GCCMkJSx9gCY0YzThRZ4doAkRaZHkGReH6Mj7S0KIyDl_hA45JwUvy3SCrl9rP230dnS61QZO3BA2YPTQT5fLE3wOzlkFZuzwzx-_vn0_058hWCMD4Mr22w6uwJ_i-dVGNzpoc4HfSWN720mHP9gARo1YXkhtfMCLoZcGV9IocLiCrsOruM8_Rg_XsvPwZP8eo0_n84_VIlm9f7OsXq0SlVKeJlA0gvOWUEZLQVsooBCUFkzyhjcqy3LC21yVbaaaAjLBKBAJSqQSQDKREn6Mpru5W2e_DOBD3Wuvog1pwA6-ZmnGYlyMiYg-v4de2sGZ6C5SggiWC5ZF6tmeGpoe2nrrdC_dWN9GG4FyB3yFxq690jEOuMPiLXJSRuMi_gitdJBBW1PZwYQoffH_0kinO1o5672Dda3204KTuqspqW-qUt9Upb6rSpTN7sluF_xVIPaudAfjP-i6Wszf_tH-Bmlc0Dk
CitedBy_id crossref_primary_10_1080_17425247_2022_2042512
crossref_primary_10_3390_molecules27144565
crossref_primary_10_1002_cbic_202200398
crossref_primary_10_1002_cbic_202400759
crossref_primary_10_1039_D2NR02994D
crossref_primary_10_1080_00958972_2022_2081079
crossref_primary_10_1002_ejic_202400243
crossref_primary_10_1002_ejic_202100468
crossref_primary_10_1021_acs_organomet_2c00553
crossref_primary_10_33224_rrch_2023_68_3_4_02
crossref_primary_10_1021_acs_inorgchem_1c02796
crossref_primary_10_1039_D3DT04017H
crossref_primary_10_3390_pharmaceutics15020689
crossref_primary_10_1039_D0CS00945H
crossref_primary_10_1021_acs_inorgchem_1c00240
crossref_primary_10_1107_S2414314624001147
Cites_doi 10.1038/icb.1969.21
10.1021/acsnano.8b08440
10.1016/j.biochi.2010.01.003
10.1002/cmdc.200500035
10.1002/ejic.201600986
10.1039/b916094a
10.1016/j.ejps.2010.12.004
10.1002/cbic.202000028
10.1002/ejic.201100497
10.1002/chem.200800507
10.1021/acsinfecdis.7b00054
10.1038/srep42717
10.1016/j.poly.2019.114261
10.1002/cbic.200400067
10.1007/BF01667023
10.1016/j.poly.2018.08.071
10.1038/170190a0
10.1021/ic3019524
10.1021/jm301077m
10.1016/j.jorganchem.2017.06.004
10.1016/j.ica.2016.04.011
10.1002/ange.200800186
10.1021/jm201220n
10.1002/ejic.201100734
10.1158/1078-0432.CCR-03-0746
10.1021/acs.organomet.7b00885
10.1039/D0SC03410J
10.1021/jacs.0c04789
10.1021/jm050251o
10.1039/C3SC53243G
10.1038/nchem.1375
10.1016/j.inoche.2008.05.012
10.1007/s10637-014-0179-1
10.1595/003214001X4526269
10.1016/B978-0-12-386454-3.01072-1
10.1128/AAC.37.3.377
10.1097/00001813-199012000-00001
10.1002/9783527695225.ch10
10.1039/C4CS00343H
10.1016/j.poly.2019.03.015
10.1002/chem.200305024
10.1021/om400446y
10.1016/j.ica.2004.11.027
10.3389/fgene.2015.00266
10.1039/C7CS00195A
10.1039/C4DT01459F
10.1021/jm021110e
10.1002/chem.201605960
10.1021/ic025538f
10.1021/acs.jmedchem.5b00455
10.1021/acs.accounts.7b00180
10.2174/1389557515666151001142012
10.1039/b508531b
10.1155/BCA/2006/83131
10.1039/c9mt00272c
10.1038/s42004-019-0213-5
10.3390/ijms20133278
10.1038/srep31973
10.1016/j.jorganchem.2005.11.029
10.1039/C8CS00304A
10.1038/srep01485
10.1039/CC9960000955
10.1021/bi00038a034
10.1039/c2dt32104a
10.1021/jacs.7b08772
10.1016/j.biochi.2011.05.012
10.1016/j.ica.2019.119025
10.1016/S0022-328X(02)01926-5
10.2174/0929867043364487
10.18632/oncotarget.22248
10.1002/anie.200800186
10.1002/cbdv.200890195
10.1155/2016/3607924
10.1039/c4dt01459f
10.1039/c3sc53243g
10.1039/c8cs00304a
10.1039/c4cs00343h
10.1039/d0sc03410j
10.1038/NCHEM.1375
10.1039/c7cs00195a
ContentType Journal Article
Copyright 2020 Wiley‐VCH GmbH
2020 Wiley-VCH GmbH.
2021 Wiley‐VCH GmbH
Copyright_xml – notice: 2020 Wiley‐VCH GmbH
– notice: 2020 Wiley-VCH GmbH.
– notice: 2021 Wiley‐VCH GmbH
DBID AAYXX
CITATION
17B
1KM
BLEPL
DTL
EGQ
HGBXW
CGR
CUY
CVF
ECM
EIF
NPM
7SR
8BQ
8FD
JG9
K9.
7X8
DOI 10.1002/chem.202004024
DatabaseName CrossRef
Web of Knowledge
Index Chemicus
Web of Science Core Collection
Science Citation Index Expanded
Web of Science Primary (SCIE, SSCI & AHCI)
Web of Science - Science Citation Index Expanded - 2021
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Engineered Materials Abstracts
METADEX
Technology Research Database
Materials Research Database
ProQuest Health & Medical Complete (Alumni)
MEDLINE - Academic
DatabaseTitle CrossRef
Web of Science
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Materials Research Database
ProQuest Health & Medical Complete (Alumni)
Engineered Materials Abstracts
Technology Research Database
METADEX
MEDLINE - Academic
DatabaseTitleList CrossRef
Web of Science

Materials Research Database
MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 1KM
  name: Index Chemicus
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/woscc/search-with-editions?editions=WOS.IC
  sourceTypes:
    Enrichment Source
    Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Chemistry
EISSN 1521-3765
EndPage 3744
ExternalDocumentID 33073884
000608556900001
10_1002_chem_202004024
CHEM202004024
Genre article
Journal Article
GrantInformation_xml – fundername: Henry Ellison Scholarship
– fundername: University of Leeds
– fundername: University of Bradford's research development fund
– fundername: Medical Research Council
  grantid: MR/T041315/1
GroupedDBID ---
-DZ
-~X
.3N
.GA
05W
0R~
10A
1L6
1OB
1OC
1ZS
29B
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5GY
5VS
66C
6J9
702
77Q
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
AAESR
AAEVG
AAHHS
AAHQN
AAMNL
AANLZ
AAONW
AAXRX
AAYCA
AAZKR
ABCQN
ABCUV
ABDBF
ABIJN
ABJNI
ABLJU
ABPVW
ACAHQ
ACCFJ
ACCZN
ACGFS
ACIWK
ACNCT
ACPOU
ACUHS
ACXBN
ACXQS
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEEZP
AEGXH
AEIGN
AEIMD
AEQDE
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALVPJ
AMBMR
AMYDB
ATUGU
AUFTA
AZBYB
AZVAB
BAFTC
BDRZF
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BROTX
BRXPI
BY8
CS3
D-E
D-F
DCZOG
DPXWK
DR2
DRFUL
DRSTM
EBD
EBS
F00
F01
F04
F5P
G-S
G.N
GNP
GODZA
H.T
H.X
HBH
HGLYW
HHY
HHZ
HZ~
IX1
J0M
JPC
KQQ
LATKE
LAW
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LYRES
MEWTI
MK4
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
P2W
P2X
P4D
PQQKQ
Q.N
Q11
QB0
QRW
R.K
RGC
RNS
ROL
RWI
RX1
RYL
SUPJJ
TN5
TWZ
UB1
UPT
V2E
V8K
W8V
W99
WBFHL
WBKPD
WH7
WIB
WIH
WIK
WJL
WOHZO
WQJ
WRC
WXSBR
WYISQ
XG1
XPP
XV2
YZZ
ZZTAW
~IA
~WT
AAYXX
AEYWJ
AGHNM
AGYGG
CITATION
17B
1KM
BLEPL
DTL
GROUPED_WOS_SCIENCE_CITATION_INDEX_EXPANDED
GROUPED_WOS_WEB_OF_SCIENCE
CGR
CUY
CVF
ECM
EIF
NPM
7SR
8BQ
8FD
JG9
K9.
7X8
ID FETCH-LOGICAL-c4134-e7b933d0121891de7e791172a3b3bc55603d6c8d5cb7e5921e0aec94aeea29403
IEDL.DBID DR2
ISICitedReferencesCount 19
ISICitedReferencesURI https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=CitingArticles&UT=000608556900001
ISSN 0947-6539
1521-3765
IngestDate Fri Jul 11 09:54:22 EDT 2025
Fri Jul 25 12:05:06 EDT 2025
Mon Jul 21 06:04:58 EDT 2025
Wed Jul 09 19:06:03 EDT 2025
Sat Sep 06 05:09:12 EDT 2025
Tue Jul 01 01:30:19 EDT 2025
Thu Apr 24 22:58:48 EDT 2025
Wed Jan 22 16:30:23 EST 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Keywords bioinorganic
ruthenium
iron
cancer
hetero-bimetallic
Language English
License 2020 Wiley-VCH GmbH.
LinkModel DirectLink
LogoURL https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg
MergedId FETCHMERGED-LOGICAL-c4134-e7b933d0121891de7e791172a3b3bc55603d6c8d5cb7e5921e0aec94aeea29403
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-9981-129X
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/chem.202004024
PMID 33073884
PQID 2490926925
PQPubID 986340
PageCount 8
ParticipantIDs proquest_journals_2490926925
wiley_primary_10_1002_chem_202004024_CHEM202004024
proquest_miscellaneous_2452094229
pubmed_primary_33073884
crossref_citationtrail_10_1002_chem_202004024
webofscience_primary_000608556900001CitationCount
webofscience_primary_000608556900001
crossref_primary_10_1002_chem_202004024
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate February 19, 2021
PublicationDateYYYYMMDD 2021-02-19
PublicationDate_xml – month: 02
  year: 2021
  text: February 19, 2021
  day: 19
PublicationDecade 2020
PublicationPlace WEINHEIM
PublicationPlace_xml – name: WEINHEIM
– name: Germany
– name: Weinheim
PublicationSubtitle A European Journal
PublicationTitle Chemistry : a European journal
PublicationTitleAbbrev CHEM-EUR J
PublicationTitleAlternate Chemistry
PublicationYear 2021
Publisher Wiley
Wiley Subscription Services, Inc
Publisher_xml – name: Wiley
– name: Wiley Subscription Services, Inc
References 2017; 7
2017; 8
2013; 3
2017; 3
2019; 13
1995; 34
2015; 33
2017; 46
2006; 691
2011; 54
2004; 5
2008; 5
2016; 2016
2020; 12
2020; 11
2008 2008; 47 120
2001; 45
2012; 55
2012; 51
2019; 165
1993; 37
2017; 846
2014; 5
2002; 41
2019; 20
2020; 176
1995; 25
2015; 44
2003; 9
2008; 28
2003; 46
1969; 47
1996; 0
2018; 37
2015; 58
2015; 6
1952; 170
2012
2011
2020; 142
2019; 2
2010; 39
2005; 358
2017; 23
2008; 14
2006
2005
2008; 11
2006; 1
2005; 48
2016; 16
2017; 454
2014; 43
2017; 139
2004; 10
2017; 50
2004; 11
1990; 1
2016; 6
2018; 155
2003; 668
2013; 32
2011; 93
2019; 48
2011; 42
2019; 498
2017
2014
2020; 21
2010; 92
2012; 4
2012; 41
e_1_2_7_5_1
e_1_2_7_3_1
e_1_2_7_7_1
e_1_2_7_19_1
e_1_2_7_17_1
e_1_2_7_62_1
e_1_2_7_15_1
e_1_2_7_41_1
e_1_2_7_64_1
e_1_2_7_1_1
e_1_2_7_13_1
e_1_2_7_43_1
e_1_2_7_66_1
e_1_2_7_11_1
e_1_2_7_45_1
e_1_2_7_68_1
Allardyce C. S. (e_1_2_7_59_1) 2001; 45
e_1_2_7_47_1
e_1_2_7_26_1
e_1_2_7_49_1
e_1_2_7_28_1
Costa S. (e_1_2_7_71_1) 2014
e_1_2_7_73_1
e_1_2_7_50_1
e_1_2_7_25_1
e_1_2_7_31_1
e_1_2_7_52_1
e_1_2_7_23_1
e_1_2_7_33_1
e_1_2_7_54_1
e_1_2_7_75_1
e_1_2_7_21_1
e_1_2_7_35_1
e_1_2_7_37_1
e_1_2_7_58_1
e_1_2_7_39_1
Rizzotto M. (e_1_2_7_72_1) 2012
e_1_2_7_6_1
e_1_2_7_4_1
e_1_2_7_8_1
e_1_2_7_18_1
e_1_2_7_16_1
e_1_2_7_40_1
e_1_2_7_61_1
e_1_2_7_2_1
e_1_2_7_14_1
e_1_2_7_42_1
e_1_2_7_63_1
e_1_2_7_12_1
e_1_2_7_44_1
e_1_2_7_65_1
Chohan Z. H. (e_1_2_7_56_1) 2006
e_1_2_7_10_1
e_1_2_7_46_1
e_1_2_7_67_1
e_1_2_7_48_1
e_1_2_7_69_1
e_1_2_7_27_1
e_1_2_7_29_1
Swarts J. C. (e_1_2_7_60_1) 2008; 28
e_1_2_7_51_1
e_1_2_7_70_1
e_1_2_7_30_1
e_1_2_7_53_1
e_1_2_7_24_1
e_1_2_7_32_1
e_1_2_7_55_1
e_1_2_7_74_1
e_1_2_7_22_2
e_1_2_7_22_1
e_1_2_7_34_1
e_1_2_7_57_1
e_1_2_7_20_1
e_1_2_7_36_1
e_1_2_7_38_1
Sava G. (e_1_2_7_9_1) 2003; 9
Bolhuis, A (WOS:000289027100001) 2011; 42
Smitten, KL (WOS:000469886300024) 2019; 13
Song, H (WOS:000306696300010) 2012; 4
Narváez-Pita, X (WOS:000407858700015) 2017; 846
Osella, D (WOS:000227975700032) 2005; 358
Chohan, ZH (WOS:000243930200001) 2006; 2006
Smitten, KL (WOS:000562597500013) 2020; 11
Sreedharan, S (WOS:000415028200052) 2017; 139
DWYER, FP (WOS:A1969C994300004) 1969; 47
Alessio, E (WOS:000397853700004) 2017
Allardyce, CS (WOS:000181644800007) 2003; 668
Shi, S (WOS:000276375100007) 2010; 92
SILVER, LL (WOS:A1993KP92100001) 1993; 37
Swarts, JC (WOS:000260554900037) 2008; 28
Nazarov, AA (WOS:000316251200002) 2013; 3
Guedes, APM (WOS:000547164400006) 2020; 12
Braga, SS (WOS:000326365900002) 2013; 32
Gill, MR (WOS:000381894800001) 2016; 6
Leijen, S (WOS:000347949400022) 2015; 33
Zeng, LL (WOS:000412141600005) 2017; 46
Lord, RM (WOS:000357139000008) 2015; 58
Abid, M (WOS:000380946500002) 2016; 16
Wang, YX (WOS:A1995TM79000004) 1995; 25
SAVA G (BCI:BCI199293113953) 1990; 1
Yano, T (WOS:000389099300022) 2017; 454
Therrien, B (WOS:000255791200021) 2008; 47
DWYER, FP (WOS:A1952UA34400005) 1952; 170
Spence, P (WOS:000562942200027) 2020; 142
Lucas, SJ (WOS:000310371500005) 2012; 41
Sava, G (WOS:000182813200041) 2003; 9
Stark, CW (WOS:000485808500001) 2019; 2
Abebe, A (WOS:000386827200001) 2016; 2016
Buriez, O (WOS:000259913900017) 2008; 14
Hartinger, CG (WOS:000260920000018) 2008; 5
Daina, A (WOS:000395280600002) 2017; 7
Marques (000608556900001.2) 2017
Laurent, Q (WOS:000428610100012) 2018; 37
Hillard, E (WOS:000202945900006) 2006; 1
Jaouen, G (WOS:000223153600006) 2004; 11
Rizzotto (000608556900001.72) 2012
NOVAKOVA, O (WOS:A1995RX23500034) 1995; 34
Top, S (WOS:000223291000012) 2004; 5
Trondl, R (WOS:000338652900001) 2014; 5
Allison, M (WOS:000524215000001) 2020; 21
Madzivire, CR (WOS:000501778900006) 2019; 498
Wang, FY (WOS:000177618300028) 2002; 41
Allardyce, CS (WOS:000207949300004) 2001; 45
Hotze, ACG (WOS:000182488300019) 2003; 46
Possato, B (WOS:000517658300017) 2020; 176
Top, S (WOS:A1996UJ31900032) 1996
Patra, M (WOS:000310120700018) 2012; 55
Munery, S (WOS:000259763800010) 2008; 11
Lee, YY (WOS:000340353100028) 2014; 43
Jin, Z (WOS:000237712600002) 2006; 691
Li, FF (WOS:000352899500019) 2015; 44
Gasser, G (WOS:000298090000002) 2011
Haider, SM (WOS:000294032100006) 2011; 93
Heinemann, F (WOS:000416497400010) 2017; 50
Costa, COD (WOS:000419562500130) 2017; 8
Pejovic, A (WOS:000449137000046) 2018; 155
Wexler (000608556900001.71) 2014
Nakayama, K (WOS:000477041100165) 2019; 20
He, M (WOS:000471358500013) 2019; 165
Patra, M (WOS:000293299100004) 2011
Basri, AM (WOS:000400945500018) 2017; 23
Sharma, A (WOS:000457793900008) 2019; 48
Rademaker-Lakhai, JM (WOS:000221784700016) 2004; 10
Top, S (WOS:000186592100008) 2003; 9
Hess, J (WOS:000410600400004) 2017; 3
Vessières, A (WOS:000229805000001) 2005; 48
Yan, YK (WOS:000232165900002) 2005
McConnell, AJ (WOS:000311173700049) 2012; 51
Shi, S (WOS:000274920400004) 2010; 39
Rubbiani, R (WOS:000297946300036) 2011; 54
Langie, SAS (WOS:000359655700001) 2015; 6
References_xml – volume: 5
  start-page: 1104
  year: 2004
  end-page: 1113
  publication-title: ChemBioChem
– volume: 48
  start-page: 3937
  year: 2005
  end-page: 3940
  publication-title: J. Med. Chem.
– volume: 43
  start-page: 12734
  year: 2014
  end-page: 12742
  publication-title: Dalton Trans.
– volume: 16
  start-page: 772
  year: 2016
  end-page: 786
  publication-title: Mini Rev. Med. Chem.
– volume: 54
  start-page: 8646
  year: 2011
  end-page: 8657
  publication-title: J. Med. Chem.
– volume: 34
  start-page: 12369
  year: 1995
  end-page: 12378
  publication-title: Biochemistry
– volume: 6
  start-page: 266
  year: 2015
  publication-title: Front. Genet.
– volume: 23
  start-page: 6341
  year: 2017
  end-page: 6356
  publication-title: Chem. Eur. J.
– volume: 12
  start-page: 547
  year: 2020
  end-page: 561
  publication-title: Metallomics
– volume: 5
  start-page: 2140
  year: 2008
  end-page: 2155
  publication-title: Chem. Biodiversity
– volume: 8
  year: 2017
  end-page: 104392
  publication-title: Oncotarget
– start-page: 1549
  year: 2017
  end-page: 1560
  publication-title: Eur. J. Inorg. Chem.
– volume: 142
  start-page: 13856
  year: 2020
  end-page: 13866
  publication-title: J. Am. Chem. Soc.
– volume: 25
  start-page: 549
  year: 1995
  end-page: 553
  publication-title: J. Chem. Crystallogr.
– volume: 846
  start-page: 113
  year: 2017
  end-page: 120
  publication-title: J. Organomet. Chem.
– volume: 47
  start-page: 203
  year: 1969
  end-page: 218
  publication-title: Aust. J. Exp. Biol. Med. Sci.
– volume: 11
  start-page: 975
  year: 2008
  end-page: 977
  publication-title: Inorg. Chem. Commun.
– volume: 41
  start-page: 4509
  year: 2002
  end-page: 4523
  publication-title: Inorg. Chem.
– volume: 155
  start-page: 382
  year: 2018
  end-page: 389
  publication-title: Polyhedron
– volume: 32
  start-page: 5626
  year: 2013
  end-page: 5639
  publication-title: Organometallics
– volume: 92
  start-page: 370
  year: 2010
  end-page: 377
  publication-title: Biochimie
– start-page: 201
  year: 2017
  end-page: 219
– volume: 3
  start-page: 645
  year: 2017
  end-page: 652
  publication-title: ACS Infect. Dis.
– volume: 47 120
  start-page: 3773 3833
  year: 2008 2008
  end-page: 3776 3836
  publication-title: Angew. Chem. Int. Ed. Angew. Chem.
– start-page: 4764
  year: 2005
  end-page: 4776
  publication-title: Chem. Commun.
– volume: 691
  start-page: 2340
  year: 2006
  end-page: 2345
  publication-title: J. Organomet. Chem.
– volume: 165
  start-page: 97
  year: 2019
  end-page: 110
  publication-title: Polyhedron
– volume: 1
  start-page: 99
  year: 1990
  end-page: 108
  publication-title: Anticancer Drugs
– volume: 51
  start-page: 12511
  year: 2012
  end-page: 12520
  publication-title: Inorg. Chem.
– volume: 170
  start-page: 190
  year: 1952
  end-page: 191
  publication-title: Nature
– volume: 6
  start-page: 31973
  year: 2016
  publication-title: Sci. Rep.
– volume: 28
  start-page: 2781
  year: 2008
  end-page: 2784
  publication-title: Anticancer Res.
– volume: 46
  start-page: 5771
  year: 2017
  end-page: 5804
  publication-title: Chem. Soc. Rev.
– start-page: 1020
  year: 2014
  end-page: 1023
– volume: 13
  start-page: 5133
  year: 2019
  end-page: 5146
  publication-title: ACS Nano
– volume: 37
  start-page: 915
  year: 2018
  end-page: 923
  publication-title: Organometallics
– volume: 11
  start-page: 8828
  year: 2020
  end-page: 8838
  publication-title: Chem. Sci.
– volume: 58
  start-page: 4940
  year: 2015
  end-page: 4953
  publication-title: J. Med. Chem.
– volume: 48
  start-page: 771
  year: 2019
  end-page: 813
  publication-title: Chem. Soc. Rev.
– start-page: 5471
  year: 2011
  end-page: 5478
  publication-title: Eur. J. Inorg. Chem.
– volume: 7
  start-page: 42717
  year: 2017
  publication-title: Sci. Rep.
– year: 2006
  publication-title: Bioinorg. Chem. Appl.
– volume: 33
  start-page: 201
  year: 2015
  end-page: 214
  publication-title: Invest. New Drugs
– volume: 45
  start-page: 62
  year: 2001
  publication-title: Platinum Metals Rev.
– volume: 176
  year: 2020
  publication-title: Polyhedron
– volume: 14
  start-page: 8195
  year: 2008
  end-page: 8203
  publication-title: Chem. Eur. J.
– volume: 21
  start-page: 1988
  year: 2020
  end-page: 1996
  publication-title: ChemBioChem
– volume: 9
  start-page: 1898
  year: 2003
  end-page: 1905
  publication-title: Clin Cancer Res
– start-page: 73
  year: 2012
  end-page: 88
– volume: 20
  start-page: 3278
  year: 2019
  publication-title: Int. J. Mol. Sci.
– volume: 498
  year: 2019
  publication-title: Inorg. Chim. Acta
– volume: 2016
  start-page: 1
  year: 2016
  publication-title: Bioinorg. Chem. Appl.
– volume: 4
  start-page: 615
  year: 2012
  end-page: 620
  publication-title: Nat. Chem.
– volume: 0
  start-page: 955
  year: 1996
  end-page: 956
  publication-title: Chem. Commun.
– volume: 358
  start-page: 1993
  year: 2005
  end-page: 1998
  publication-title: Inorganica Chim. Acta
– start-page: 3295
  year: 2011
  end-page: 3302
  publication-title: Eur. J. Inorg. Chem.
– volume: 41
  start-page: 13800
  year: 2012
  end-page: 13802
  publication-title: Dalton Trans.
– volume: 11
  start-page: 2505
  year: 2004
  end-page: 2517
  publication-title: Curr. Med. Chem.
– volume: 55
  start-page: 8790
  year: 2012
  end-page: 8798
  publication-title: J. Med. Chem.
– volume: 10
  start-page: 3717
  year: 2004
  end-page: 3727
  publication-title: Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res.
– volume: 3
  start-page: 1485
  year: 2013
  publication-title: Sci. Rep.
– volume: 2
  start-page: 108
  year: 2019
  publication-title: Commun. Chem.
– volume: 1
  start-page: 551
  year: 2006
  end-page: 559
  publication-title: ChemMedChem
– volume: 9
  start-page: 5223
  year: 2003
  end-page: 5236
  publication-title: Chem. Eur. J.
– volume: 5
  start-page: 2925
  year: 2014
  end-page: 2932
  publication-title: Chem. Sci.
– volume: 454
  start-page: 162
  year: 2017
  end-page: 170
  publication-title: Inorg. Chim. Acta.
– volume: 93
  start-page: 1239
  year: 2011
  end-page: 1251
  publication-title: Biochimie
– volume: 39
  start-page: 2490
  year: 2010
  end-page: 2493
  publication-title: Dalton Trans.
– volume: 37
  start-page: 377
  year: 1993
  end-page: 383
  publication-title: Antimicrob. Agents Chemother.
– volume: 668
  start-page: 35
  year: 2003
  end-page: 42
  publication-title: J. Organomet. Chem.
– volume: 139
  start-page: 15907
  year: 2017
  end-page: 15913
  publication-title: J. Am. Chem. Soc.
– volume: 44
  start-page: 2529
  year: 2015
  end-page: 2542
  publication-title: Chem. Soc. Rev.
– volume: 42
  start-page: 313
  year: 2011
  end-page: 317
  publication-title: Eur. J. Pharm. Sci.
– volume: 46
  start-page: 1743
  year: 2003
  end-page: 1750
  publication-title: J. Med. Chem.
– volume: 50
  start-page: 2727
  year: 2017
  end-page: 2736
  publication-title: Acc. Chem. Res.
– ident: e_1_2_7_50_1
  doi: 10.1038/icb.1969.21
– ident: e_1_2_7_52_1
  doi: 10.1021/acsnano.8b08440
– ident: e_1_2_7_19_1
  doi: 10.1016/j.biochi.2010.01.003
– ident: e_1_2_7_43_1
  doi: 10.1002/cmdc.200500035
– ident: e_1_2_7_5_1
  doi: 10.1002/ejic.201600986
– ident: e_1_2_7_18_1
  doi: 10.1039/b916094a
– ident: e_1_2_7_48_1
  doi: 10.1016/j.ejps.2010.12.004
– ident: e_1_2_7_46_1
  doi: 10.1002/cbic.202000028
– ident: e_1_2_7_34_1
  doi: 10.1002/ejic.201100497
– ident: e_1_2_7_39_1
  doi: 10.1002/chem.200800507
– ident: e_1_2_7_31_1
  doi: 10.1021/acsinfecdis.7b00054
– ident: e_1_2_7_65_1
  doi: 10.1038/srep42717
– ident: e_1_2_7_13_1
  doi: 10.1016/j.poly.2019.114261
– ident: e_1_2_7_38_1
  doi: 10.1002/cbic.200400067
– ident: e_1_2_7_61_1
  doi: 10.1007/BF01667023
– ident: e_1_2_7_74_1
  doi: 10.1016/j.poly.2018.08.071
– ident: e_1_2_7_49_1
  doi: 10.1038/170190a0
– ident: e_1_2_7_16_1
  doi: 10.1021/ic3019524
– ident: e_1_2_7_33_1
  doi: 10.1021/jm301077m
– ident: e_1_2_7_37_1
  doi: 10.1016/j.jorganchem.2017.06.004
– ident: e_1_2_7_17_1
  doi: 10.1016/j.ica.2016.04.011
– ident: e_1_2_7_22_2
  doi: 10.1002/ange.200800186
– ident: e_1_2_7_32_1
  doi: 10.1021/jm201220n
– ident: e_1_2_7_35_1
  doi: 10.1002/ejic.201100734
– ident: e_1_2_7_3_1
  doi: 10.1158/1078-0432.CCR-03-0746
– ident: e_1_2_7_23_1
  doi: 10.1021/acs.organomet.7b00885
– volume: 9
  start-page: 1898
  year: 2003
  ident: e_1_2_7_9_1
  publication-title: Clin Cancer Res
– start-page: 73
  volume-title: Search Antibact. Agents
  year: 2012
  ident: e_1_2_7_72_1
– ident: e_1_2_7_53_1
  doi: 10.1039/D0SC03410J
– ident: e_1_2_7_21_1
  doi: 10.1021/jacs.0c04789
– ident: e_1_2_7_44_1
  doi: 10.1021/jm050251o
– ident: e_1_2_7_7_1
  doi: 10.1039/C3SC53243G
– ident: e_1_2_7_28_1
  doi: 10.1038/nchem.1375
– ident: e_1_2_7_62_1
  doi: 10.1016/j.inoche.2008.05.012
– ident: e_1_2_7_4_1
  doi: 10.1007/s10637-014-0179-1
– volume: 45
  start-page: 62
  year: 2001
  ident: e_1_2_7_59_1
  publication-title: Platinum Metals Rev.
  doi: 10.1595/003214001X4526269
– start-page: 1020
  volume-title: Encycl. Toxicol. Third
  year: 2014
  ident: e_1_2_7_71_1
  doi: 10.1016/B978-0-12-386454-3.01072-1
– ident: e_1_2_7_58_1
  doi: 10.1128/AAC.37.3.377
– ident: e_1_2_7_8_1
  doi: 10.1097/00001813-199012000-00001
– ident: e_1_2_7_2_1
  doi: 10.1002/9783527695225.ch10
– ident: e_1_2_7_75_1
  doi: 10.1039/C4CS00343H
– ident: e_1_2_7_27_1
  doi: 10.1016/j.poly.2019.03.015
– ident: e_1_2_7_40_1
  doi: 10.1002/chem.200305024
– ident: e_1_2_7_36_1
  doi: 10.1021/om400446y
– ident: e_1_2_7_42_1
  doi: 10.1016/j.ica.2004.11.027
– ident: e_1_2_7_70_1
  doi: 10.3389/fgene.2015.00266
– ident: e_1_2_7_10_1
  doi: 10.1039/C7CS00195A
– ident: e_1_2_7_47_1
  doi: 10.1039/C4DT01459F
– ident: e_1_2_7_66_1
  doi: 10.1021/jm021110e
– ident: e_1_2_7_63_1
  doi: 10.1002/chem.201605960
– ident: e_1_2_7_64_1
  doi: 10.1021/ic025538f
– ident: e_1_2_7_26_1
  doi: 10.1021/acs.jmedchem.5b00455
– ident: e_1_2_7_29_1
  doi: 10.1021/acs.accounts.7b00180
– ident: e_1_2_7_1_1
  doi: 10.2174/1389557515666151001142012
– ident: e_1_2_7_24_1
  doi: 10.1039/b508531b
– year: 2006
  ident: e_1_2_7_56_1
  publication-title: Bioinorg. Chem. Appl.
  doi: 10.1155/BCA/2006/83131
– ident: e_1_2_7_12_1
  doi: 10.1039/c9mt00272c
– ident: e_1_2_7_30_1
  doi: 10.1038/s42004-019-0213-5
– ident: e_1_2_7_68_1
  doi: 10.3390/ijms20133278
– ident: e_1_2_7_15_1
  doi: 10.1038/srep31973
– ident: e_1_2_7_57_1
  doi: 10.1016/j.jorganchem.2005.11.029
– ident: e_1_2_7_69_1
  doi: 10.1039/C8CS00304A
– ident: e_1_2_7_14_1
  doi: 10.1038/srep01485
– ident: e_1_2_7_41_1
  doi: 10.1039/CC9960000955
– ident: e_1_2_7_67_1
  doi: 10.1021/bi00038a034
– ident: e_1_2_7_25_1
  doi: 10.1039/c2dt32104a
– ident: e_1_2_7_51_1
  doi: 10.1021/jacs.7b08772
– ident: e_1_2_7_20_1
  doi: 10.1016/j.biochi.2011.05.012
– ident: e_1_2_7_54_1
  doi: 10.1016/j.ica.2019.119025
– ident: e_1_2_7_55_1
  doi: 10.1016/S0022-328X(02)01926-5
– ident: e_1_2_7_45_1
  doi: 10.2174/0929867043364487
– ident: e_1_2_7_11_1
  doi: 10.18632/oncotarget.22248
– ident: e_1_2_7_22_1
  doi: 10.1002/anie.200800186
– volume: 28
  start-page: 2781
  year: 2008
  ident: e_1_2_7_60_1
  publication-title: Anticancer Res.
– ident: e_1_2_7_6_1
  doi: 10.1002/cbdv.200890195
– ident: e_1_2_7_73_1
  doi: 10.1155/2016/3607924
– volume: 45
  start-page: 62
  year: 2001
  ident: WOS:000207949300004
  article-title: Ruthenium in Medicine: Current Clinical Uses and Future Prospects
  publication-title: PLATINUM METALS REVIEW
– volume: 142
  start-page: 13856
  year: 2020
  ident: WOS:000562942200027
  article-title: Beyond Solvent Exclusion: i-Motif Detecting Capability and an Alternative DNA Light-Switching Mechanism in a Ruthenium(II) Polypyridyl Complex
  publication-title: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
  doi: 10.1021/jacs.0c04789
– volume: 2
  start-page: ARTN 108
  year: 2019
  ident: WOS:000485808500001
  article-title: Solute-solvent electronic interaction is responsible for initial charge separation in ruthenium complexes [Ru(bpy)3]2+ and [Ru(phen)3]2+
  publication-title: COMMUNICATIONS CHEMISTRY
  doi: 10.1038/s42004-019-0213-5
– volume: 165
  start-page: 97
  year: 2019
  ident: WOS:000471358500013
  article-title: Photoinduced anticancer effect evaluation of ruthenium(II) polypyridyl complexes toward human lung cancer A549 cells
  publication-title: POLYHEDRON
  doi: 10.1016/j.poly.2019.03.015
– volume: 2016
  start-page: ARTN 3607924
  year: 2016
  ident: WOS:000386827200001
  article-title: Synthesis and Assessment of Antibacterial Activities of Ruthenium(III) Mixed Ligand Complexes Containing 1,10-Phenanthroline and Guanide
  publication-title: BIOINORGANIC CHEMISTRY AND APPLICATIONS
  doi: 10.1155/2016/3607924
– volume: 43
  start-page: 12734
  year: 2014
  ident: WOS:000340353100028
  article-title: Ruthenium(II) complexes containing functionalised β-diketonate ligands: developing a ferrocene mimic for biosensing applications
  publication-title: DALTON TRANSACTIONS
  doi: 10.1039/c4dt01459f
– volume: 155
  start-page: 382
  year: 2018
  ident: WOS:000449137000046
  article-title: Synthesis, characterization and antimicrobial activity of novel 3-ferroceny1-2-pyrazolyl-1,3-thiazolidin-4-ones
  publication-title: POLYHEDRON
  doi: 10.1016/j.poly.2018.08.071
– volume: 5
  start-page: 2925
  year: 2014
  ident: WOS:000338652900001
  article-title: NKP-1339, the first ruthenium-based anticancer drug on the edge to clinical application
  publication-title: CHEMICAL SCIENCE
  doi: 10.1039/c3sc53243g
– volume: 20
  start-page: ARTN 3278
  year: 2019
  ident: WOS:000477041100165
  article-title: Regulation of Gene Expression under Hypoxic Conditions
  publication-title: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
  doi: 10.3390/ijms20133278
– volume: 23
  start-page: 6341
  year: 2017
  ident: WOS:000400945500018
  article-title: Bis-picolinamide Ruthenium(III) Dihalide Complexes: Dichloride-to-Diiodide Exchange Generates Single trans Isomers with High Potency and Cancer Cell Selectivity
  publication-title: CHEMISTRY-A EUROPEAN JOURNAL
  doi: 10.1002/chem.201605960
– volume: 16
  start-page: 772
  year: 2016
  ident: WOS:000380946500002
  article-title: Ruthenium Complexes: An Emerging Ground to the Development of Metallopharmaceuticals for Cancer Therapy
  publication-title: MINI-REVIEWS IN MEDICINAL CHEMISTRY
  doi: 10.2174/1389557515666151001142012
– volume: 33
  start-page: 201
  year: 2015
  ident: WOS:000347949400022
  article-title: Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy
  publication-title: INVESTIGATIONAL NEW DRUGS
  doi: 10.1007/s10637-014-0179-1
– volume: 41
  start-page: 13800
  year: 2012
  ident: WOS:000310371500005
  article-title: Synthesis of iridium and ruthenium complexes with (N,N), (N,O) and (O,O) coordinating bidentate ligands as potential anti-cancer agents
  publication-title: DALTON TRANSACTIONS
  doi: 10.1039/c2dt32104a
– volume: 668
  start-page: 35
  year: 2003
  ident: WOS:000181644800007
  article-title: Synthesis and characterisation of some water soluble ruthenium(II)-arene complexes and an investigation of their antibiotic and antiviral properties
  publication-title: JOURNAL OF ORGANOMETALLIC CHEMISTRY
– volume: 41
  start-page: 4509
  year: 2002
  ident: WOS:000177618300028
  article-title: Reactions of a ruthenium(II) arene antitumor complex with cysteine and methionine
  publication-title: INORGANIC CHEMISTRY
  doi: 10.1021/ic025538f
– volume: 5
  start-page: 1104
  year: 2004
  ident: WOS:000223291000012
  article-title: Selective estrogen-receptor modulators (SERMs) in the cyclopentadienylrhenium tricarbonyl series:: Synthesis and biological behaviour
  publication-title: CHEMBIOCHEM
  doi: 10.1002/cbic.200400067
– volume: 691
  start-page: 2340
  year: 2006
  ident: WOS:000237712600002
  article-title: Synthesis, characterization, and biological evaluation of novel ferrocene-triadimefon analogues
  publication-title: JOURNAL OF ORGANOMETALLIC CHEMISTRY
  doi: 10.1016/j.jorganchem.2005.11.029
– volume: 6
  start-page: ARTN 31973
  year: 2016
  ident: WOS:000381894800001
  article-title: A ruthenium polypyridyl intercalator stalls DNA replication forks, radiosensitizes human cancer cells and is enhanced by Chk1 inhibition
  publication-title: SCIENTIFIC REPORTS
  doi: 10.1038/srep31973
– volume: 3
  start-page: 645
  year: 2017
  ident: WOS:000410600400004
  article-title: Ferrocenyl, Ruthenocenyl, and Benzyl Oxamniquine Derivatives with Cross-Species Activity against Schistosoma mansoni and Schistosoma haematobium
  publication-title: ACS INFECTIOUS DISEASES
  doi: 10.1021/acsinfecdis.7b00054
– volume: 48
  start-page: 771
  year: 2019
  ident: WOS:000457793900008
  article-title: Hypoxia-targeted drug delivery
  publication-title: CHEMICAL SOCIETY REVIEWS
  doi: 10.1039/c8cs00304a
– volume: 139
  start-page: 15907
  year: 2017
  ident: WOS:000415028200052
  article-title: Multimodal Super-resolution Optical Microscopy Using a Transition-Metal-Based Probe Provides Unprecedented Capabilities for Imaging Both Nuclear Chromatin and Mitochondria
  publication-title: JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
  doi: 10.1021/jacs.7b08772
– volume: 48
  start-page: 3937
  year: 2005
  ident: WOS:000229805000001
  article-title: Modification of the estrogenic properties of diphenols by the incorporation of ferrocene.: Generation of antiproliferative effects in vitro
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/jm050251o
– volume: 11
  start-page: 2505
  year: 2004
  ident: WOS:000223153600006
  article-title: The first organometallic selective estrogen receptor modulators (SERMs) and their relevance to breast cancer
  publication-title: CURRENT MEDICINAL CHEMISTRY
– volume: 47
  start-page: 203
  year: 1969
  ident: WOS:A1969C994300004
  article-title: BIOLOGICAL ACTIONS OF 1,10-PHENANTHROLINE AND 2,2'-BIPYRIDINE HYDROCHLORIDES QUATERNARY SALTS AND METAL CHELATES AND RELATED COMPOUNDS .1. BACTERIOSTATIC ACTION ON SELECTED GRAM-POSITIVE GRAM-NEGATIVE AND ACID-FAST BACTERIA
  publication-title: AUSTRALIAN JOURNAL OF EXPERIMENTAL BIOLOGY AND MEDICAL SCIENCE
– start-page: 1020
  year: 2014
  ident: 000608556900001.71
  publication-title: Encycl. Toxicol
– start-page: 4764
  year: 2005
  ident: WOS:000232165900002
  article-title: Organometallic chemistry, biology and medicine: ruthenium arene anticancer complexes
  publication-title: CHEMICAL COMMUNICATIONS
  doi: 10.1039/b508531b
– volume: 2006
  start-page: ARTN 83131
  year: 2006
  ident: WOS:000243930200001
  article-title: Metal-based antibacterial and antifungal agents: Synthesis, characterization, and in vitro biological evaluation of Co(II), Cu(II), Ni(II), and Zn(II) complexes with amino acid-derived compounds
  publication-title: BIOINORGANIC CHEMISTRY AND APPLICATIONS
  doi: 10.1155/BCA/2006/83131
– volume: 51
  start-page: 12511
  year: 2012
  ident: WOS:000311173700049
  article-title: Luminescent Properties of Ruthenium(II) Complexes with Sterically Expansive Ligands Bound to DNA Defects
  publication-title: INORGANIC CHEMISTRY
  doi: 10.1021/ic3019524
– volume: 10
  start-page: 3717
  year: 2004
  ident: WOS:000221784700016
  article-title: A phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent
  publication-title: CLINICAL CANCER RESEARCH
– volume: 14
  start-page: 8195
  year: 2008
  ident: WOS:000259913900017
  article-title: Reactivity and Antiproliferative Activity of Ferrocenyl-Tamoxifen Adducts with Cyclodextrins against Hormone-Independent Breast-Cancer Cell Lines
  publication-title: CHEMISTRY-A EUROPEAN JOURNAL
  doi: 10.1002/chem.200800507
– volume: 6
  start-page: ARTN 266
  year: 2015
  ident: WOS:000359655700001
  article-title: The comet assay: part, present, and future
  publication-title: FRONTIERS IN GENETICS
  doi: 10.3389/fgene.2015.00266
– volume: 34
  start-page: 12369
  year: 1995
  ident: WOS:A1995RX23500034
  article-title: CORRELATION BETWEEN CYTOTOXICITY AND DNA-BINDING OF POLYPYRIDYL RUTHENIUM COMPLEXES
  publication-title: BIOCHEMISTRY
– start-page: 1549
  year: 2017
  ident: WOS:000397853700004
  article-title: Thirty Years of the Drug Candidate NAMI-A and the Myths in the Field of Ruthenium Anticancer Compounds: A Personal Perspective
  publication-title: EUROPEAN JOURNAL OF INORGANIC CHEMISTRY
  doi: 10.1002/ejic.201600986
– volume: 8
  start-page: 104367
  year: 2017
  ident: WOS:000419562500130
  article-title: Novel piplartine-containing ruthenium complexes: synthesis, cell growth inhibition, apoptosis induction and ROS production on HCT116 cells
  publication-title: ONCOTARGET
  doi: 10.18632/oncotarget.22248
– volume: 1
  start-page: 99
  year: 1990
  ident: BCI:BCI199293113953
  article-title: METAL COMPLEXES OF RUTHENIUM ANTINEOPLASTIC PROPERTIES AND PERSPECTIVES
  publication-title: Anti-Cancer Drugs
– volume: 358
  start-page: 1993
  year: 2005
  ident: WOS:000227975700032
  article-title: FACS analysis of oxidative stress induced on tumour cells by SERMs
  publication-title: INORGANICA CHIMICA ACTA
  doi: 10.1016/j.ica.2004.11.027
– volume: 12
  start-page: 547
  year: 2020
  ident: WOS:000547164400006
  article-title: Heterobimetallic Ru(ii)/Fe(ii) complexes as potent anticancer agents against breast cancer cells, inducing apoptosis through multiple targets
  publication-title: METALLOMICS
  doi: 10.1039/c9mt00272c
– volume: 39
  start-page: 2490
  year: 2010
  ident: WOS:000274920400004
  article-title: Molecular "light switch" for G-quadruplexes and i-motif of human telomeric DNA: [Ru(phen)2(dppz)]2+
  publication-title: DALTON TRANSACTIONS
  doi: 10.1039/b916094a
– volume: 32
  start-page: 5626
  year: 2013
  ident: WOS:000326365900002
  article-title: A New Age for Iron: Antitumoral Ferrocenes
  publication-title: ORGANOMETALLICS
  doi: 10.1021/om400446y
– volume: 44
  start-page: 2529
  year: 2015
  ident: WOS:000352899500019
  article-title: Ruthenium complexes as antimicrobial agents
  publication-title: CHEMICAL SOCIETY REVIEWS
  doi: 10.1039/c4cs00343h
– volume: 47
  start-page: 3773
  year: 2008
  ident: WOS:000255791200021
  article-title: The "Complex-in-a-Complex" cations [(acac)2M⊂RU6(p-iPrC6H4Me)6(tpt)2(dhbq)3]6+:: A Trojan horse for cancer cells
  publication-title: ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
  doi: 10.1002/anie.200800186
– volume: 37
  start-page: 915
  year: 2018
  ident: WOS:000428610100012
  article-title: Applying a Trojan Horse Strategy to Ruthenium Complexes in the Pursuit of Novel Antibacterial Agents
  publication-title: ORGANOMETALLICS
  doi: 10.1021/acs.organomet.7b00885
– volume: 7
  start-page: ARTN 42717
  year: 2017
  ident: WOS:000395280600002
  article-title: SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules
  publication-title: SCIENTIFIC REPORTS
  doi: 10.1038/srep42717
– volume: 9
  start-page: 1898
  year: 2003
  ident: WOS:000182813200041
  article-title: Dual action of NAMI-A in inhibition of solid tumor metastasis: Selective targeting of metastatic cells and binding to collagen
  publication-title: CLINICAL CANCER RESEARCH
– volume: 11
  start-page: 8828
  year: 2020
  ident: WOS:000562597500013
  article-title: Mononuclear ruthenium(ii) theranostic complexes that function as broad-spectrum antimicrobials in therapeutically resistant pathogens through interaction with DNA
  publication-title: CHEMICAL SCIENCE
  doi: 10.1039/d0sc03410j
– volume: 9
  start-page: 5223
  year: 2003
  ident: WOS:000186592100008
  article-title: Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens:: Evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines
  publication-title: CHEMISTRY-A EUROPEAN JOURNAL
  doi: 10.1002/chem.200305024
– volume: 498
  start-page: ARTN 119025
  year: 2019
  ident: WOS:000501778900006
  article-title: Anticancer, antifungal and antibacterial potential of bis(β-ketoiminato) ruthenium(II) carbonyl complexes
  publication-title: INORGANICA CHIMICA ACTA
  doi: 10.1016/j.ica.2019.119025
– start-page: 3295
  year: 2011
  ident: WOS:000293299100004
  article-title: Synthesis of Optically Active Ferrocene-Containing Platensimycin Derivatives with a C6-C7 Substitution Pattern
  publication-title: EUROPEAN JOURNAL OF INORGANIC CHEMISTRY
  doi: 10.1002/ejic.201100497
– volume: 176
  start-page: ARTN 114261
  year: 2020
  ident: WOS:000517658300017
  article-title: Anticancer activity and DNA interaction of ruthenium acetate clusters bearing azanaphthalene ancillary ligands
  publication-title: POLYHEDRON
  doi: 10.1016/j.poly.2019.114261
– volume: 846
  start-page: 113
  year: 2017
  ident: WOS:000407858700015
  article-title: Ferrocene-steroid conjugates: Synthesis, structure and biological activity
  publication-title: JOURNAL OF ORGANOMETALLIC CHEMISTRY
  doi: 10.1016/j.jorganchem.2017.06.004
– volume: 50
  start-page: 2727
  year: 2017
  ident: WOS:000416497400010
  article-title: Critical Overview of the Use of Ru(II) Polypyridyl Complexes as Photosensitizers in One-Photon and Two-Photon Photodynamic Therapy
  publication-title: ACCOUNTS OF CHEMICAL RESEARCH
  doi: 10.1021/acs.accounts.7b00180
– volume: 3
  start-page: ARTN 1485
  year: 2013
  ident: WOS:000316251200002
  article-title: Synthesis and characterization of a new class of anti-angiogenic agents based on ruthenium clusters
  publication-title: SCIENTIFIC REPORTS
  doi: 10.1038/srep01485
– volume: 93
  start-page: 1239
  year: 2011
  ident: WOS:000294032100006
  article-title: A structural analysis of G-quadruplex/ligand interactions
  publication-title: BIOCHIMIE
  doi: 10.1016/j.biochi.2011.05.012
– volume: 4
  start-page: 615
  year: 2012
  ident: WOS:000306696300010
  article-title: Crystal structure of Δ-[Ru(bpy)2dppz]2+ bound to mismatched DNA reveals side-by-side metalloinsertion and intercalation
  publication-title: NATURE CHEMISTRY
  doi: 10.1038/NCHEM.1375
– start-page: 73
  year: 2012
  ident: 000608556900001.72
  publication-title: Search Antibact. Agents
– volume: 454
  start-page: 162
  year: 2017
  ident: WOS:000389099300022
  article-title: Anticancer activity of heterodinuclear ruthenium(II)-platinum(II) complexes as photochemotherapeutic agents
  publication-title: INORGANICA CHIMICA ACTA
  doi: 10.1016/j.ica.2016.04.011
– volume: 25
  start-page: 549
  year: 1995
  ident: WOS:A1995TM79000004
  article-title: Crystal structure, physical, and photophysical properties of a ruthenium(II) bipyridine diazafluorenone complex
  publication-title: JOURNAL OF CHEMICAL CRYSTALLOGRAPHY
– volume: 54
  start-page: 8646
  year: 2011
  ident: WOS:000297946300036
  article-title: Comparative in Vitro Evaluation of N-Heterocyclic Carbene Gold(I) Complexes of the Benzimidazolylidene Type
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/jm201220n
– start-page: 201
  year: 2017
  ident: 000608556900001.2
  publication-title: Ruthenium Complexes
– volume: 5
  start-page: 2140
  year: 2008
  ident: WOS:000260920000018
  article-title: KP1019, A New Redox-Active Anticancer Agent - Preclinical Development and Results of a Clinical Phase I Study in Tumor Patients
  publication-title: CHEMISTRY & BIODIVERSITY
– volume: 11
  start-page: 975
  year: 2008
  ident: WOS:000259763800010
  article-title: Synthesis and characterization of bis(bipyridine)ruthenium(II) complexes with bromo or protected ethynyl β-diketonato ligands
  publication-title: INORGANIC CHEMISTRY COMMUNICATIONS
  doi: 10.1016/j.inoche.2008.05.012
– volume: 46
  start-page: 1743
  year: 2003
  ident: WOS:000182488300019
  article-title: New cytotoxic and water-soluble bis(2-phenylazopyridine)ruthenium(II) complexes
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/jm021110e
– volume: 46
  start-page: 5771
  year: 2017
  ident: WOS:000412141600005
  article-title: The development of anticancer ruthenium(II) complexes: from single molecule compounds to nanomaterials
  publication-title: CHEMICAL SOCIETY REVIEWS
  doi: 10.1039/c7cs00195a
– volume: 28
  start-page: 2781
  year: 2008
  ident: WOS:000260554900037
  article-title: Cytotoxicity of a Series of Ferrocene-containing β-Diketones
  publication-title: ANTICANCER RESEARCH
– start-page: 955
  year: 1996
  ident: WOS:A1996UJ31900032
  article-title: Ferrocenyl hydroxytamoxifen: A prototype for a new range of oestradiol receptor site-directed cytotoxics
  publication-title: CHEMICAL COMMUNICATIONS
– volume: 1
  start-page: 551
  year: 2006
  ident: WOS:000202945900006
  article-title: A series of unconjugated ferrocenyl phenols:: Prospects as anticancer agents
  publication-title: CHEMMEDCHEM
  doi: 10.1002/cmdc.200500035
– volume: 42
  start-page: 313
  year: 2011
  ident: WOS:000289027100001
  article-title: Antimicrobial activity of ruthenium-based intercalators
  publication-title: EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
  doi: 10.1016/j.ejps.2010.12.004
– volume: 21
  start-page: 1988
  year: 2020
  ident: WOS:000524215000001
  article-title: β-Diketonate versus β-Ketoiminate: The Importance of a Ferrocenyl Moiety in Improving the Anticancer Potency
  publication-title: CHEMBIOCHEM
  doi: 10.1002/cbic.202000028
– volume: 37
  start-page: 377
  year: 1993
  ident: WOS:A1993KP92100001
  article-title: DISCOVERY AND DEVELOPMENT OF NEW ANTIBIOTICS - THE PROBLEM OF ANTIBIOTIC-RESISTANCE
  publication-title: ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
– volume: 55
  start-page: 8790
  year: 2012
  ident: WOS:000310120700018
  article-title: Ferrocenyl Derivatives of the Anthelmintic Praziquantel: Design, Synthesis, and Biological Evaluation
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/jm301077m
– start-page: 5471
  year: 2011
  ident: WOS:000298090000002
  article-title: Preparation and Biological Evaluation of Di-Hetero-Organometallic-Containing PNA Bioconjugates
  publication-title: EUROPEAN JOURNAL OF INORGANIC CHEMISTRY
  doi: 10.1002/ejic.201100734
– volume: 58
  start-page: 4940
  year: 2015
  ident: WOS:000357139000008
  article-title: Hypoxia-Sensitive Metal β-Ketoiminato Complexes Showing Induced Single-Strand DNA Breaks and Cancer Cell Death by Apoptosis
  publication-title: JOURNAL OF MEDICINAL CHEMISTRY
  doi: 10.1021/acs.jmedchem.5b00455
– volume: 92
  start-page: 370
  year: 2010
  ident: WOS:000276375100007
  article-title: Interaction of [Ru(bpy)2(dppz)]2+ with human telomeric DNA: Preferential binding to G-quadruplexes over i-motif
  publication-title: BIOCHIMIE
  doi: 10.1016/j.biochi.2010.01.003
– volume: 170
  start-page: 190
  year: 1952
  ident: WOS:A1952UA34400005
  article-title: BIOLOGICAL ACTIVITY OF COMPLEX IONS
  publication-title: NATURE
– volume: 13
  start-page: 5133
  year: 2019
  ident: WOS:000469886300024
  article-title: Using Nanoscopy To Probe the Biological Activity of Antimicrobial Leads That Display Potent Activity against Pathogenic, Multidrug Resistant, Gram-Negative Bacteria
  publication-title: ACS NANO
  doi: 10.1021/acsnano.8b08440
SSID ssj0009633
Score 2.4455352
Snippet The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl β‐diketonate complexes, [(bpy)2Ru(Fc‐acac)][PF6] (bpy=2,2′‐bipyridine;...
The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl β‐diketonate complexes, [(bpy) 2 Ru(Fc‐acac)][PF 6 ] (bpy=2,2′‐bipyridine;...
The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl beta-diketonate complexes, [(bpy)(2)Ru(Fc-acac)][PF6] (bpy=2,2 '-bipyridine;...
The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl β-diketonate complexes, [(bpy) Ru(Fc-acac)][PF ] (bpy=2,2'-bipyridine;...
The synthesis and characterization of new bis(bipyridine)ruthenium(II) ferrocenyl β-diketonate complexes, [(bpy)2 Ru(Fc-acac)][PF6 ] (bpy=2,2'-bipyridine;...
Source Web of Science
SourceID proquest
pubmed
webofscience
crossref
wiley
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 3737
SubjectTerms Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Bimetals
Bioassays
bioinorganic
Biotechnology
Cancer
Carboplatin
Cell Line, Tumor
Chemistry
Chemistry, Multidisciplinary
Cisplatin
Colon
Colorectal cancer
Comet Assay
Coordination Complexes - chemistry
Coordination Complexes - pharmacology
Coordination compounds
Cytotoxicity
Damage detection
DNA damage
hetero-bimetallic
Humans
Hypoxia
iron
Microbial Sensitivity Tests
Neoplasms - drug therapy
Neoplasms - pathology
Oxaliplatin
Pancreatic cancer
Pancreatic carcinoma
Physical Sciences
Platinum
Ruthenium
Ruthenium - chemistry
Ruthenium - pharmacology
Ruthenium compounds
Science & Technology
Toxicity
Tumor cell lines
Title Bis(bipyridine)ruthenium(II) Ferrocenyl β‐Diketonate Complexes: Exhibiting Nanomolar Potency against Human Cancer Cell Lines
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fchem.202004024
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestApp=WOS&DestLinkType=FullRecord&UT=000608556900001
https://www.ncbi.nlm.nih.gov/pubmed/33073884
https://www.proquest.com/docview/2490926925
https://www.proquest.com/docview/2452094229
Volume 27
WOS 000608556900001
WOSCitedRecordID wos000608556900001
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwEB6hcigXKOUvtFRGqkR7SJs4v-bWTbtqESCEqNRbZCeTKmqarbJZieXSPgLPwoPwEDwJnvy1W4RAcIxiJxp7PPPZM_4GYFMjaspX880wk5bpqpSChHZiErkY50pl2NAuvnvvHx67b068kxu3-Ft-iOHAjVZGY69pgUs13b0mDdUy0U1ymmXtZ7QRpoQtQkUfr_mjtHa1teTdwCQO1p610eK7i90XvdIvUPOWV1oEso0nGj8A2cvQJqCc7cxqtZN8uUXv-D9CrsD9DqayvVavHsIdLFdhOeqrwz2Cy1E-3VL5xbzKtffD7Yoy5ct8dr51dLTNxliRYyznBfv-7cfV1_38DGs6p0dGBqjAzzh9zQ6oOHdOeddMG_nJOe2y2YcJofg5k6cy19CVNVEGFpFyVizComBvKVP_MRyPDz5Fh2ZXzMFMtJ90TQyUcJyUKORCYacYYKDtbMCloxyVeBp4OamfhKmXqAA9wW20JCbClYiSC9dynsBSOSnxGTC9pUstZWHmYeZKyw8FV3aYuU6WpFJJywCzn8w46ZjOqeBGEbcczTymYY2HYTXg1dD-ouX4-G3L9V434m6tT2O9gbUE9wX3DHg5vNbTQaEXWeJkRm0o3UhrvzDgaatTw68cMrNhqD--eVPJhvcNZ06oR0g0oRgD7L9pFnWCE7VBbQBvtOwP4sVEwzE8Pf-XTmtwj1PWD5XMEeuwVFczfKFhW6024O7eaH803miW6E9lcjqu
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BOZQL70eggJEq0R7SJs7T3CDtahe2FUKtxC2ykwmKmmarbFZiucBP4LfwQ_gR_BI8eZUtQiA4RhknGnte9oy_AdjUETXVq_lmmEnLdFVKSUI7MQlcjHOlMmxgFw8O_fGx--qd11cT0l2YFh9iOHAjzWjsNSk4HUjvnqOGaqboKjkts3Y0l-EKtfUm3dx7e44gpeWr7SbvBiahsPa4jRbfXR2_6pd-CTYv-KXVULbxRaProHou2hKUk51FrXaSjxcAHv-LzRtwrYtU2YtWtG7CJSxvwXrUN4i7DZ9e5vMtlZ8tq1w7QNyuqFi-zBenW5PJNhthRb6xXBbs29fvn7_s5SdY01E9MrJBBX7A-XO2T_25cyq9ZtrOz05po83ezCiQXzL5XuY6emVNooFFJJ8Vi7Ao2JSK9e_A8Wj_KBqbXT8HM9Gu0jUxUMJxUkKRC4WdYoCBNrUBl45yVOLp2MtJ_SRMvUQF6AluoyUxEa5ElFy4lnMX1spZifeB6V1daikLMw8zV1p-KLiyw8x1siSVSloGmP1qxkkHdk49N4q4hWnmMU1rPEyrAc8G-rMW5uO3lBu9cMSdus9jvYe1BPcF9wx4OrzWy0HZF1nibEE0VHGkFUAYcK8VquFXDlnaMNQf3_xZyob3DWxOqGdINNkYA-y_IYs6xgndoDaAN2L2B_ZiQuIYnh78y6AnsD4-OpjG08nh64dwlVMREHXQERuwVlcLfKSjuFo9bvT0BwfbPVU
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NbtQwEB5BkYBL-S0EChipEu0hbeL8mhtku-pCqSpEpd4iO5mgqGl2ld2VulzgEXgWHoSH4Enw5K_dIgSCY5RxorHnz57xNwAbOqKmejXfDDNpma5KKUloJyaBi3GuVIY17OK7A3_vyH1z7B1fuMXf4EP0B26kGbW9JgWfpNnOOWio5oluktMqaz9zFa65vhXS9mvw_hxASotX00zeDUwCYe1gGy2-szx-2S39EmteckvLkWztioa3QHZMNBUoJ9vzmdpOPl3Cd_wfLm_DahunsleNYN2BK1jehRtR1x7uHnx-nU83VT5ZVLl2f7hVUal8mc9PN0ejLTbEijxjuSjY928_vnwd5Cc4o4N6ZGSBCjzD6Uu2S925cyq8ZtrKj09pm80OxxTGL5j8KHMdu7I6zcAiks6KRVgUbJ9K9e_D0XD3Q7Rntt0czEQ7StfEQAnHSQlDLhR2igEG2tAGXDrKUYmnIy8n9ZMw9RIVoCe4jZbERLgSUXLhWs4arJTjEh8C03u61FIWZh5mrrT8UHBlh5nrZEkqlbQMMLvFjJMW6pw6bhRxA9LMY5rWuJ9WA1709JMG5OO3lOudbMStsk9jvYO1BPcF9wx43r_Wy0G5F1nieE40VG-kxV8Y8KCRqf5XDtnZMNQf37goZP37GjQn1DMk6lyMAfbfkEUt44RtMDOA11L2B_ZiwuHonx79y6BncP1wMIz3RwdvH8NNThVA1D5HrMPKrJrjEx3CzdTTWkt_Ajm7PA0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Bis%28bipyridine%29ruthenium%28II%29+Ferrocenyl+%CE%B2%E2%80%90Diketonate+Complexes%3A+Exhibiting+Nanomolar+Potency+against+Human+Cancer+Cell+Lines&rft.jtitle=Chemistry+%3A+a+European+journal&rft.au=Allison%2C+Matthew&rft.au=Caram%C3%A9s%E2%80%90M%C3%A9ndez%2C+Pablo&rft.au=Pask%2C+Christopher+M.&rft.au=Phillips%2C+Roger+M.&rft.date=2021-02-19&rft.issn=0947-6539&rft.eissn=1521-3765&rft.volume=27&rft.issue=11&rft.spage=3737&rft.epage=3744&rft_id=info:doi/10.1002%2Fchem.202004024&rft.externalDBID=10.1002%252Fchem.202004024&rft.externalDocID=CHEM202004024
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0947-6539&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0947-6539&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0947-6539&client=summon